Use of a 2.5% Cross-Linked Polyacrylamide Hydrogel in the Management of Joint Lameness in a Population of Flat Racing Thoroughbreds: A Pilot Study.

This research explores the effectiveness of a 2.5% cross-linked polyacrylamide hydrogel (PAAG) in treating joint lameness in racehorses caused by osteoarthritis. The study found significant improvements in the condition of the horses treated with this solution, suggesting that it is a safe and effective treatment.

Study Overview

• The research was a prospective longitudinal study aimed at understanding the efficacy of a 2.5% cross-linked polyacrylamide hydrogel (PAAG) in treating joint lameness in Thoroughbred racehorses due to osteoarthritis.
• Osteoarthritis is a common affliction in equine athletes, causing up to 60% of all lameness. Thus, effective management of this condition is essential for the health and performance of the horses.

Study Methodology

• The study involved 49 flat-racing Thoroughbreds from a single training facility. The horses were all treated with the 2.5% cross-linked PAAG.
• The effectiveness of the treatment was measured by noting the improvement in lameness grades at various intervals – weeks 1, 4, 12, and 24 – compared to the baseline lameness at week 0 (before the treatment).

Study Findings

• The findings from the study were highly promising. There was a significant improvement in lameness grades at all intervals checked when compared to the baseline.
• At week 1, the improvement was statistically significant (P < .01), and it improved further at week 4 (P < .001), week 12 (P < .001), and week 24 (P < .001).

Conclusion and Further Research

• The study concluded that the 2.5% cross-linked PAAG is a safe and effective treatment for managing joint lameness caused by osteoarthritis in Thoroughbred racehorses.
• Despite the positive results from this pilot study, the researchers are calling for further blinded and controlled studies to fully evaluate the efficacy of the 2.5% cross-linked PAAG treatment and understand its mode of action.